Lynn Macdonald

This inventor holds 192 USPTO granted patents and 92 published patent applications, plus 31 CIPO patents and 106 EPO patents, primarily in Genetically Modified Mice (CPC class A01K67-0278). Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc., Duke University. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lynn Macdonald. Retrieved from https://idiyas.com/inventor/lynn-macdonald

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 192 (Patent Applications = 92)

% Patents Active = 90.6

CIPO Patents = 31 (Patent Applications = 41)

EPO Patents = 106 (Patent Applications = 153)

Average Co-Inventor Count = 4.8

ph-index = 16

Forward Citations = 1,213(Granted Patents)

Forward Citations (Not Self Cited) = 604(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

White Plains, NY (US) (2011 - 2020)
Harrison, NY (US) (2016 - 2024)

Company Filing History:

183 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

8 out of 49

Regeneran Pharmaceuticals, Inc.

4. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Genetically Modified Mice

T Cell Receptors

Immunoglobulin Sequences

Humanized Antibodies

Targeted Genetic Modification

B-Cell Activating Factor

Antigen-Binding Proteins

Nuclease-Mediated DNA Assembly

Humanized Light Chain

Fc-Gamma Receptors

Limited Immunoglobulin Repertoire

Osteoarthritis Treatment

192 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760122 - MICE THAT MAKE VL BINDING PROTEINS (2026-10-13),

2. 12745761 - NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS (2026-09-29),

3. 12677812 - Humanized non-human animals with restricted immunoglobulin heavy chain loci (2026-07-14),

4. 12672644 - MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORS (2026-07-07),

5. 12637698 - METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS (2026-05-26),

6. 12628801 - HUMANIZED UNIVERSAL LIGHT CHAIN MICE (2026-05-19),

7. 12582105 - GENETICALLY MODIFIED T CELL RECEPTOR MICE (2026-03-24),

8. 12553064 - METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING (2026-02-17),

9. 12543713 - MICE THAT MAKE HEAVY CHAIN ANTIBODIES (2026-02-10),

10. 12543711 - Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences (2026-02-10),

11. 12538905 - MOUSE HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE (2026-02-03),

12. 12486335 - MICE THAT MAKE VL BINDING PROTEINS (2025-12-02),

13. 12441784 - Human antibodies to artemin and methods of use thereof (2025-10-14),

14. 12433266 - Humanized light chain mice (2025-10-07),

15. 12433265 - Non-human animals having a humanized a proliferation-inducing ligand gene (2025-10-07),

Title: The Innovative Journey of Lynn Macdonald

Introduction: Lynn Macdonald, a talented inventor based in Harrison, NY (US), has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Lynn Macdonald holds several patents in various technological domains, showcasing his versatility and ingenuity in inventing new solutions to complex problems.

Career Highlights: With a career spanning over two decades, Lynn Macdonald has consistently pushed the boundaries of innovation. His work has been recognized for its impact on improving efficiency and functionality in different industries.

Collaborations: Throughout his career, Lynn Macdonald has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. These collaborations have been instrumental in turning his ideas into reality.

Conclusion: Lynn Macdonald's passion for innovation and his dedication to creating solutions that make a difference have solidified his reputation as a respected inventor in the technology sector. His continued pursuit of excellence promises a future filled with groundbreaking inventions that will shape the world we live in.

Profile summary based on public USPTO records.